VANCOUVER, BC / January 23, 2018 / CVR Medical Corp. (TSX.V: CVM) (FRANKFURT: B3BN) (OTCQB: CRRVF) (“CVR Medical”) announces the commencement of clinical data acquisition by the Carotid Stenotic Scan (CSS) device at the renowned Henry Ford Hospital. There is currently one wireless CSS device fully deployed within the Henry Ford system, with two additional devices slated for implementation in the subsequent weeks. This clinical trial plays a crucial role in accelerating clinical substantiation for the CSS device and shortening the timeline for CVR’s imminent FDA submission.
The trial will be overseen by Primary Investigator, Dr. Judith Lin, Senior Staff Surgeon and Medical Director of Henry Ford’s Clinical Vascular Laboratory. Recognized for excellence in the area of cardiology and cardiovascular surgery, the team at Henry Ford possesses the expertise and experience necessary to successfully validate the worth of the CSS device.
“With FDA submission in our sights, quality input from leading healthcare institutions is critical,” states CVR Chief Operations Officer Tony Robinson. “Many companies have a product they hope to market to the end user, but we at CVR take a different approach. If we can arm the clinician with a tool allowing them to function more efficiently and improve their quality of care, this supersedes the need to convince them of anything. We intend to improve outcomes, a result that markets itself.”
For additional information on the organization, leadership and current news, please visit the company website www.CVRMed.com.
About CVR Medical
CVR Medical is a company that is involved in an equal parts joint venture with CVR Global Inc. (the “Joint Venture”). The Joint Venture operates in the medical industry focused on the commercialization of a proprietary subsonic, infrasonic, and low frequency sound wave analysis technology and has patents to a diagnostic device designed to detect and measure carotid arterial stenosis. CVR Medical is managed by a proven technical team. CVR Medical trades on the TSX Venture Exchange under the symbol CVM.
ON BEHALF OF THE BOARD:
(signed) “Peter Bakema”
CEO, President & Director
For further information please contact:
Peter Bakema, CEO, President and Director
Telephone: (734) 718-5115
Brisco Capital Partners Corp.
Scott Koyich, President
Telephone: (403) 262-9888
This press release contains forward-looking information that involves various risks and uncertainties regarding future events related to the Joint Venture. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements and are not guarantees of future performance of the Company. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management’s current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, including: (1) a downturn in general economic conditions in North America and internationally, (2) the inherent uncertainties and speculative nature associated with commercialization of technology and the practice of medicine, (3) a change in health regulations, (4) any number of events or causes which may delay or cease commercialization and development of the Joint Venture, (5) the risk that the Company or the Joint Venture does not execute its business plan, (6) inability to retain key employees, (7) inability to finance operations and growth, and (8) other factors beyond the Company’s control. These forward-looking statements are made as of the date of this news release and, except as required by law, the Company assumes no obligation to update these forward-looking statements, or to update the reasons why actual results differed from those projected in the forward-looking statements.
THE TSX VENTURE EXCHANGE INC. HAS NEITHER APPROVED NOR DISAPPROVED THE CONTENTS OF THIS PRESS RELEASE. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.